Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Genfit   /   Genfit 2019

Aandeel Genfit PSE:GNFT.FR, FR0004163111

Laatste koers (eur) Verschil Volume
3,940   -0,040   (-1,01%) Dagrange 3,905 - 4,005 169.890   Gem. (3M) 312,7K

Genfit 2019

Volgen
117 Posts
Pagina: «« 1 2 3 4 5 6 »» | Laatste | Omlaag ↓
  1. forum rang 10 DeZwarteRidder 3 maart 2019 13:09
    quote:

    Dr. Bob schreef op 3 maart 2019 13:05:

    Onderstaand de events die Genfit de komende maanden zal bijwonen.

    March 12-14, 2019, Barclays Global Healthcare Conference, Miami, US
    March 17-19, 2019, Annual ROTH Conference, Orange County, US
    March 28, 2019, ROTH Battle of the NASH Thrones Spring Conference, New York, US
    April 4-5, 2019, CM-CIC Market Solutions Forum by ESN, Paris, France
    April 7-9, 2019, LHC Wainwright & Co. Global Life Sciences Conference, London, UK
    April 9-10, 2019, Portzamparc MidCap Conference, Paris, France
    April 11-14, 2019, 2019 International Liver Congress™, Vienna, Austria
    April 16-17, 2019 Kempen Life Sciences Conference, Amsterdam, The Netherlands
    April 16-17, 2019, SmallCap Event, Paris, France
    April 22-25, 2019, 3rd Annual NASH Summit, Boston, US
    April 26-27, 2019 - 1st International Workshop of the SHIVER Network, Montreal Canada
    June 7 - 11, 2019 - US79th Scientific Sessions of the ADA, San Francisco, US
    July 11 - 12, 2019 - NASH Meeting 2019, Paris, France
    Geen wonder dat ze zoveel geld nodig hebben......
  3. [verwijderd] 5 maart 2019 18:34
    quote:

    DeZwarteRidder schreef op 21 februari 2019 16:17:

    Bij Intercept hebben ze inmiddels ontdekt dat de stijging naar ca 125 USD op een grote vergissing berust. De koers staat nu op ca 92 USD.
    ??

    Intercept Pharmaceuticals, Inc. Real Time Stock Quotes

    $108.6

     

    3.96  3.78%

    3/5/2019 12:31:25 PM | Real-Time

  6. [verwijderd] 14 maart 2019 19:49
    GENFIT announces Launch of Proposed Global Offering and Nasdaq listing

    Lille (France), Cambridge (Massachusetts, United States), March 14, 2019 – GENFIT S.A. (Euronext Paris: GNFT – ISIN: FR0004163111) (“Genfit” or the “Company”), a French biopharmaceutical company focused on discovering and developing drug candidates and diagnostic solutions targeting liver diseases, in particular those of metabolic origin, today announced its intention to issue and sell, subject to market and other conditions, 5,000,000 of its ordinary shares in a global offering to specified categories of investors, comprised of an initial public offering of American Depositary Shares (“ADSs”), each representing one ordinary share, in the United States (the “U.S. Offering”), and a concurrent private placement of ordinary shares in Europe (including France) and other countries outside of the United States (the “European Private Placement,” and together with the U.S. Offering, the “Global Offering”).

    GENFIT intends to grant the underwriters for the offering (the “Underwriters”) a 30-day option to purchase additional ADSs and/or ordinary shares in an aggregate amount of up to 15% of the total number of ADSs and ordinary shares proposed to be sold in the Global Offering.

    All securities to be sold in the Global Offering will be offered by GENFIT. GENFIT’s ordinary shares are listed on Euronext Paris under the symbol “GNFT”. GENFIT has applied to list the ADSs to be sold in the U.S. Offering on the Nasdaq Global Market under the ticker symbol “GNFT”.

    SVB Leerink and Barclays are acting as joint global coordinators for the Global Offering and joint bookrunners for the U.S. Offering. Roth Capital Partners and H.C. Wainwright & Co. are acting as co-managers of the U.S. Offering. Bryan, Garnier & Co. Limited and Natixis are acting as joint bookrunners with respect to the European Private Placement.

    The offering price per ADS in U.S. dollars and the corresponding offering price per ordinary share in euros, as well as the final number of ADSs and/or ordinary shares sold in the Global Offering, will be determined following a bookbuilding process commencing immediately. The offering price per ADS and per ordinary share will be at least equal to the volume-weighted average price of the Company’s ordinary shares on Euronext Paris during a window of five to 30 consecutive trading days (as decided by the Company) within the 30 trading days preceding the date on which the final offering price is determined, reduced by a maximum discount of 15%.

    On an indicative basis, the completion of the Global Offering, assuming the issuance of 5,000,000 ordinary shares (including in the form of ADSs), would result in a dilution of approximately 14% of the Company’s outstanding share capital on a non-diluted basis, and approximately 16% of the Company’s outstanding share capital on a non-diluted basis in the event that the Underwriters exercise in full their option to purchase additional ADSs and/or ordinary shares .

    The ADSs and/or ordinary shares will be issued through a capital increase without shareholders’ preferential subscription rights and for the benefit of a specified category of persons within the meaning of Article L.225-138 of the French Commercial Code (Code de commerce) and pursuant to the seventeenth and eighteenth resolutions of the Company’s combined general shareholders’ meeting held on June 15, 2018. Under the authority granted by the shareholders in the seventeenth resolution, the ordinary shares and ADSs may only be purchased initially by industrial or commercial companies in the pharmaceutical/biotech sector or investment fund companies or fund management companies or collective savings managing funds governed by French or foreign law or any other legal entity (including a trust) or natural person, investing in the pharmaceutical/biotech sector, that is qualified to invest in a private placement. In order to purchase ordinary shares and/or ADSs in the Global Offering, potential investors will be required to execute and provide to the Underwriters an investor letter representing that they satisfy the foregoing investor criteria.

    The closings of the U.S. Offering and the European Private Placement will occur simultaneously, will be conditioned on each other and are expected to occur on the third trading day after the final pricing and allocation of the Global Offering.

    The Company expects to use the net proceeds from the Global Offering as follows (assuming an exchange rate of €1.00 = $1.1243, the exchange rate on March 8, 2019):

    approximately €13.3 million ($15.0 million) to prepare for the potential commercialization of elafibranor for the treatment of nonalcoholic steatohepatitis (“NASH”) by building out its commercial infrastructure;
    approximately €44.5 million ($50.0 million) to complete its ongoing Phase 3 clinical development of elafibranor for the treatment of NASH through to, at least, the submission of a new drug application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) and European Medicines Agency (“EMA”) and the launch of the Phase 4 clinical trial;
    approximately €31.1 million ($35.0 million) to conduct and complete its planned global Phase 3 clinical trial of elafibranor for the treatment of primary biliary cholangitis (“PBC”);
    approximately €5.3 million ($6.0 million) to advance the commercial development of an in vitro diagnostic (“IVD”) test designed to identify NASH patients, including the launch of the test as a laboratory-developed test and completion of work required to obtain regulatory approval for the IVD kit from the FDA;
    approximately €5.3 million ($6.0 million) to advance its research program on the use of elafibranor as a potential backbone for combination therapies in order to launch two planned proof-of-concept studies; and
    the remainder, if any, for working capital and general corporate purposes.

    The securities referred to in this press release will be offered only by means of a prospectus. Copies of the preliminary prospectus relating to and describing the terms of the Global Offering may be obtained from SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by telephone at (800) 808-7525, ext. 6132, or by email at syndicate@svbleerink.com; or from Barclays Capital Inc., c/o Broadridge Financial Solutions, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (888) 603-5847, or by email at barclaysprospectus@broadridge.com.

    A registration statement on Form F-1 relating to these securities has been filed with the U.S. Securities and Exchange Commission but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective.

    Application will be made to list the new ordinary shares to be issued pursuant to the Global Offering on the regulated market of Euronext in Paris pursuant to a listing prospectus subject to a visa application with the French Autorité des marchés financiers (“AMF“) and comprising the 2018 Reference Document (Document de Référence) of the Company registered with the AMF on February 27, 2019 under number D. 19-0078 and a Securities Note (Note d’opération), including a summary of the prospectus. Copies of the 2018 Reference Document are available free of charge at the Company’s head office located at Parc Eurasanté, 885, avenue Eugène Avinée, 59120 Loos, France, on the Company’s website (www.genfit.com) and on the website of the AMF (www.amf-france.org).
  9. [verwijderd] 22 maart 2019 07:38
    NON-INVASIVE DIAGNOSTIC OF NON-ALCOHOLIC FATTY LIVER DISEASES, NONALCOHOLIC STEATOHEPATITIS AND/OR LIVER FIBROSIS op WIPO Patentscope

    FIELD OF THE INVENTION: "The present invention relates to a novel non-invasive method for the diagnosis of a nonalcoholic fatty liver disease, in particular non-alcoholic steatohepatitis, and/or liver fibrosis."

    patentscope.wipo.int/search/en/detail...

    patentscope.wipo.int/search/en/detail...
  10. forum rang 10 DeZwarteRidder 24 maart 2019 13:47
    Conatus Pharmaceuticals shares tank after missing primary endpoint in clinical trial of its liver disease drug
    08:40 06 Dec 2018
    Results from the Phase 2b clinical trial of liver disease drug Emriscan failed to show a meaningful difference when compared with the placebo

    Conatus focuses on the development of therapies to treat liver disease

    Conatus Pharmaceuticals Inc (NASDAQ:CNAT) shares lost about half their value in Thursday pre-market trading following disappointing results from its Phase 2b clinical trial of its liver disease drug Emriscan.

    The biotech’s ENCORE-PH clinical trial found that Emriscan failed to meet the primary endpoint of the study after being unable to show a meaningful difference when compared with the placebo.

    Shares fell 51% to $2.20 in Thursday pre-market trading.

    Emriscan is an oral drug designed to reduce the activity of enzymes that cause inflammation and cell death, which may be able to affect the progression of liver disease.

    “We believe data from the ENCORE-PH clinical trial as well as data from our two ongoing ENCORE trials that will be available in 2019 will warrant future discussions with regulatory authorities regarding potential pivotal trials in patients with NASH and advanced liver disease,” said Executive Vice President of Clinical Development David T. Hagerty in the company’s press release.

    The double-blind, placebo-controlled study, conducted alongside drug manufacturing giant Novartis AG (NYSE:NVS), enrolled 263 patients with nonalcoholic steatohepatitis, a condition caused by a buildup of fat in the liver resulting in inflammation and damage to the organ.

    Conatus is a San Diego-based biotech focused on the development of therapies to treat liver disease.
  16. [verwijderd] 28 maart 2019 09:44
    quote:

    DeZwarteRidder schreef op 24 maart 2019 13:47:

    Conatus Pharmaceuticals shares tank after missing primary endpoint in clinical trial of its liver disease drug
    08:40 06 Dec 2018
    Results from the Phase 2b clinical trial of liver disease drug Emriscan failed to show a meaningful difference when compared with the placebo

    Conatus focuses on the development of therapies to treat liver disease

    Conatus Pharmaceuticals Inc (NASDAQ:CNAT) shares lost about half their value in Thursday pre-market trading following disappointing results from its Phase 2b clinical trial of its liver disease drug Emriscan.

    The biotech’s ENCORE-PH clinical trial found that Emriscan failed to meet the primary endpoint of the study after being unable to show a meaningful difference when compared with the placebo.

    Shares fell 51% to $2.20 in Thursday pre-market trading.

    Emriscan is an oral drug designed to reduce the activity of enzymes that cause inflammation and cell death, which may be able to affect the progression of liver disease.

    “We believe data from the ENCORE-PH clinical trial as well as data from our two ongoing ENCORE trials that will be available in 2019 will warrant future discussions with regulatory authorities regarding potential pivotal trials in patients with NASH and advanced liver disease,” said Executive Vice President of Clinical Development David T. Hagerty in the company’s press release.

    The double-blind, placebo-controlled study, conducted alongside drug manufacturing giant Novartis AG (NYSE:NVS), enrolled 263 patients with nonalcoholic steatohepatitis, a condition caused by a buildup of fat in the liver resulting in inflammation and damage to the organ.

    Conatus is a San Diego-based biotech focused on the development of therapies to treat liver disease.

    Je wordt niet rijk door het vergelijken van appels en peren.
  17. forum rang 10 DeZwarteRidder 29 maart 2019 18:51
    Short Target Viking Therapeutics Wins Over Only Cautious Analyst
    By Cristin Flanagan
    29 maart 2019 14:47 CET

    VKTX
    VIKING THERAPEUT
    10.17
    USD
    +1.66+19.50%

    Short-seller target Viking Therapeutics Inc. got a boost from Wall Street on Friday as the only cautious analyst upgraded the stock to a buy.

    Viking shares climbed as much as 5.8 percent in New York after SVB Leerink analyst Pasha Sarraf raised his rating to outperform from market perform and more than doubled his 12-month price target to $21 from $10. All nine analysts tracked by Bloomberg now recommend buying shares even as bearish bets on Viking have risen to 47 percent of the available float, according to data from financial analytics firm S3 Partners.
    Viking shares beaten back from highs as shorts circle

    The drugmaker is among companies racing to introduce the first treatments for the fatty liver disease known as NASH. Sarraf, who started covering the stock in February, said data this week that showed a low dose of Viking’s drug worked at least as well as higher doses were “persuasive.” The company will probably start a mid-stage study in NASH with “minor to no restrictions on who they will be allowed to study,” he said.
  18. Wil Helmus 29 maart 2019 22:17
    www.nashbiotechs.com/nash-biotech-ana...

    ELAFIBRANOR

    ELAFIBRANOR seems the dreamed complement for SELONSERTIB, the GOLDEN phase 2b studies now prove its strong action on NASH and on the main components of the metabolic syndrome. the drug is now the most advanced in clinical studies and is likely to be the first treatment that will access the market. 

    The RESOLV IT Phase III study already started its recruitment and plan to finish the recruitment of the first 1000 patientsneeded for the subpart H accelareted agreement before spring 2018. It mean intermediate results at end  2019 and a possible agreement and access to the market at the end of 2020.

    ELAFIBRANOR is a perfect complementary to a treatment targeting advanced fibrosis and cirrhosis. 

    To date, GENFIT, at less than 1b$,  is clearly underevaluated , however GENFIT knows very well the value of the gold nugget that have in their hands withELAFIBRANOR. They are not for sale !  except maybe for a very substantial offer that could exceed maybe $ 10 billion.

    It remains the option of an hostile takeover  but it could imply to pay more than the required price because other laboratories seems also very interested in GENFIT and an hostile takeover would generate an expensive battle on the price offering. 

    Nevertheless ELAFIBRANOR  is the most advanced compound on NASH treatment with a good safety and no noticable adverse effects, if GILEAD  are ready to put  more than $ 10 billion on the table to buyGENFIT,  it probably worth the gamble to be the first on the market. The alternative is a licence deal with GENFIT or a co development  deal as they have done withGALAPAGOS.

    They’ll probably choose to wait for the Ph3 intermediatre results in Q4 2019 , but then, with positives results, the drug could become priceless !

  20. [verwijderd] 30 maart 2019 10:35
    quote:

    DeZwarteRidder schreef op 29 maart 2019 18:51:

    Short Target Viking Therapeutics Wins Over Only Cautious Analyst
    By Cristin Flanagan
    29 maart 2019 14:47 CET

    VKTX
    VIKING THERAPEUT
    10.17
    USD
    +1.66+19.50%

    Short-seller target Viking Therapeutics Inc. got a boost from Wall Street on Friday as the only cautious analyst upgraded the stock to a buy.

    Viking shares climbed as much as 5.8 percent in New York after SVB Leerink analyst Pasha Sarraf raised his rating to outperform from market perform and more than doubled his 12-month price target to $21 from $10. All nine analysts tracked by Bloomberg now recommend buying shares even as bearish bets on Viking have risen to 47 percent of the available float, according to data from financial analytics firm S3 Partners.
    Viking shares beaten back from highs as shorts circle

    The drugmaker is among companies racing to introduce the first treatments for the fatty liver disease known as NASH. Sarraf, who started covering the stock in February, said data this week that showed a low dose of Viking’s drug worked at least as well as higher doses were “persuasive.” The company will probably start a mid-stage study in NASH with “minor to no restrictions on who they will be allowed to study,” he said.
    Als de prijs van dit aandeel 100% stijgt, is het weer terug op het prijsniveau van 6 maanden geleden.
117 Posts
Pagina: «« 1 2 3 4 5 6 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee